Sign In
‹ Back to lectures
Antiretroviral Medications

Long-Acting, Injectable Cabotegravir-Rilpivirine (CAB-RPV)

March 22, 2023
Dr. Brian Wood introduces long acting, injectable Cabotegravir-Rilpivirine, the first approved intramuscular ART. He reviews patient eligibility, the two dosing options (every 1-month or every 2 months), and recommendations on how to manage a planned missed injection. He also discusses clinical trial data and a recent update to HHS guidelines about the timing of a genotype resistance assay after stoppage of this ART.
 PDF  Powerpoint
Brian R. Wood, MD
Professor of Medicine
Division of Allergy & Infectious Diseases
University of Washington
Disclosures
Disclosures for Brian R. Wood, MD
None

Since you've received 80% or better on this quiz, you may claim continuing education credit.

You seem to have a popup blocker enabled. If you want to skip this dialog please Always allow popup windows for the online course.